1life Healthcare (ONEM) 10-Q 4 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Jul. 26, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-39203
Entity Registrant Name	1LIFE HEALTHCARE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	76-0707204
Entity Address, Address Line One	One Embarcadero Center
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94111
City Area Code	(415)
Local Phone Number	814-0927
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ONEM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		137,802,443
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001404123
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 503,238	$ 112,975
Short-term marketable securities	150,559	570,023
Accounts receivable, net	55,982	67,895
Inventories	3,950	7,113
Prepaid expenses and other current assets	43,025	16,693
Total current assets	756,754	774,699
Restricted cash	1,895	1,911
Property and equipment, net	144,770	126,037
Right-of-use assets	165,653	138,840
Goodwill	26,866	21,301
Deferred income taxes	2,656	2,656
Other assets	29,047	5,546
Total assets	1,127,641	1,070,990
Current liabilities:
Accounts payable	12,462	12,654
Accrued expenses	56,037	46,527
Deferred revenue, current	43,605	35,966
Operating lease liabilities, current	20,656	17,418
Other current liabilities	21,988	4,861
Total current liabilities	154,748	117,426
Operating lease liabilities, non-current	181,952	153,614
Convertible senior notes	308,907	241,233
Deferred revenue, non-current	6,750	7,624
Other non-current liabilities	2,840	2,618
Total liabilities	655,197	522,515
Commitments and contingencies (Note 13)
Stockholders' Equity:
Common stock, $0.001 par value, 1,000,000 and 1,000,000 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 137,774 and 134,472 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	138	134
Additional paid-in capital	916,460	918,118
Accumulated deficit	(444,162)	(369,785)
Accumulated other comprehensive income	8	8
Total stockholders' equity	472,444	548,475
Total liabilities and stockholders' equity	$ 1,127,641	$ 1,070,990

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares, issued	137,774,000	134,472,000
Common stock, shares, outstanding	137,774,000	134,472,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Net revenue	$ 120,416	$ 78,000	$ 241,768	$ 156,756
Operating expenses:
Cost of care, exclusive of depreciation and amortization shown separately below	67,922	53,450	138,014	104,999
Sales and marketing	10,570	9,777	23,259	20,933
General and administrative	77,196	38,311	141,541	78,177
Depreciation and amortization	7,292	5,175	13,899	10,388
Total operating expenses	162,980	106,713	316,713	214,497
Loss from operations	(42,564)	(28,713)	(74,945)	(57,741)
Other income (expense), net:
Interest income	79	366	184	1,400
Interest expense	(2,842)	(1,976)	(5,685)	(2,029)
Change in fair value of redeemable convertible preferred stock warrant liability	0	0	0	(6,560)
Total other expense, net	(2,763)	(1,610)	(5,501)	(7,189)
Loss before income taxes	(45,327)	(30,323)	(80,446)	(64,930)
Provision for (benefit from) income taxes	(4,040)	(22)	159	(72)
Net loss	(41,287)	(30,301)	(80,605)	(64,858)
Less: Net loss attributable to noncontrolling interest	0	0	0	(704)
Net loss attributable to 1Life Healthcare, Inc. stockholders	$ (41,287)	$ (30,301)	$ (80,605)	$ (64,154)
Net loss per share attributable to 1Life Healthcare, Inc. stockholders — basic (in usd per share)	$ (0.30)	$ (0.24)	$ (0.59)	$ (0.61)
Net loss per share attributable to 1Life Healthcare, Inc. stockholders — diluted (in usd per share)	$ (0.30)	$ (0.24)	$ (0.59)	$ (0.61)
Weighted average common shares outstanding — basic (in shares)	136,788	126,150	137,045	105,517
Weighted average common shares outstanding — diluted (in shares)	136,788	126,150	137,045	105,517

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (41,287)	$ (30,301)	$ (80,605)	$ (64,858)
Other comprehensive loss:
Net unrealized loss on short-term marketable securities	(12)	(51)	0	(7)
Comprehensive loss	(41,299)	(30,352)	(80,605)	(64,865)
Less: Comprehensive loss attributable to noncontrolling interest	0	0	0	(704)
Comprehensive loss attributable to 1Life Healthcare, Inc. stockholders	$ (41,299)	$ (30,352)	$ (80,605)	$ (64,161)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect Period of Adoption Adjustment	Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Additional Paid-In CapitalCumulative Effect Period of Adoption Adjustment	Accumulated Deficit	Accumulated DeficitCumulative Effect Period of Adoption Adjustment	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity (Deficit) Attributable to 1Life Healthcare, Inc. Stockholders	Total Stockholders' Equity (Deficit) Attributable to 1Life Healthcare, Inc. StockholdersCumulative Effect Period of Adoption Adjustment	Noncontrolling Interest
Beginning balances, Shares at Dec. 31, 2019				18,952
Beginning balances at Dec. 31, 2019	$ (184,031)			$ 19	$ 93,945		$ (281,068)		$ 38	$ (187,066)		$ 3,035
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering (in shares)			(86,257)	86,257
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering	402,564		$ (402,564)	$ 86	402,478					402,564
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $23,631 (in shares)				20,125
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $23,631	258,119			$ 20	258,099					258,119
Fair value adjustment to redeemable convertible preferred stock warrants upon conversion into common stock warrants	13,740				13,740					13,740
Exercise of stock options (in shares)				294
Exercise of stock options	1,534				1,534					1,534
Exercise of common stock warrants (in shares)				11
Exercise of common stock warrants	73				73					73
Cashless exercise of common stock warrants (in shares)				464
Cashless exercise of common stock warrants	1			$ 1						1
Stock-based compensation expense	10,325				10,325					10,325
Net unrealized gain on short-term marketable securities	44								44	44
Net loss	(34,557)						(33,853)			(33,853)		(704)
Ending balances, Shares at Mar. 31, 2020				126,103
Ending balances at Mar. 31, 2020	467,812			$ 126	780,194		(314,921)		82	465,481		2,331
Beginning balances, Shares at Dec. 31, 2019			86,252
Beginning balances at Dec. 31, 2019			$ 402,488
Increase (Decrease) in Temporary Equity [Roll Forward]
Exercise of redeemable convertible preferred stock warrant (in shares)			5
Exercise of redeemable convertible preferred stock warrant	0		$ 76							0
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering (in shares)			(86,257)	86,257
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering	402,564		$ (402,564)	$ 86	402,478					402,564
Ending balances, Shares at Mar. 31, 2020			0
Ending balances at Mar. 31, 2020			$ 0
Beginning balances, Shares at Dec. 31, 2019				18,952
Beginning balances at Dec. 31, 2019	(184,031)			$ 19	93,945		(281,068)		38	(187,066)		3,035
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized gain on short-term marketable securities	(7)
Net loss	(64,858)
Ending balances, Shares at Jun. 30, 2020				126,206
Ending balances at Jun. 30, 2020	518,208			$ 126	863,273		(345,222)		31	518,208		0
Beginning balances, Shares at Dec. 31, 2019			86,252
Beginning balances at Dec. 31, 2019			$ 402,488
Ending balances, Shares at Jun. 30, 2020			0
Ending balances at Jun. 30, 2020			$ 0
Beginning balances, Shares at Mar. 31, 2020				126,103
Beginning balances at Mar. 31, 2020	467,812			$ 126	780,194		(314,921)		82	465,481		2,331
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reimbursed secondary offering issuance costs					784
Exercise of stock options (in shares)				103
Exercise of stock options	562				562					562
Stock-based compensation expense	8,363				8,363					8,363
Net unrealized gain on short-term marketable securities	(51)								(51)	(51)
Equity component of convertible senior notes, net of issuance costs of $2,243					73,370
VIE deconsolidation					0							(2,331)
Net loss	(30,301)						(30,301)			(30,301)
Ending balances, Shares at Jun. 30, 2020				126,206
Ending balances at Jun. 30, 2020	518,208			$ 126	863,273		(345,222)		31	518,208		$ 0
Beginning balances, Shares at Mar. 31, 2020			0
Beginning balances at Mar. 31, 2020			$ 0
Ending balances, Shares at Jun. 30, 2020			0
Ending balances at Jun. 30, 2020			$ 0
Beginning balances, Shares at Dec. 31, 2020				134,472
Beginning balances at Dec. 31, 2020	548,475			$ 134	918,118		(369,785)		8	548,475
Beginning balances (ASU 2020-06) at Dec. 31, 2020		$ (66,737)				$ (73,393)		$ 6,656			$ (66,737)
Beginning balances (ASC 326) at Dec. 31, 2020		(428)						(428)			(428)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)				2,584
Exercise of stock options	13,479			$ 3	13,476					13,479
Issuance of common stock for settlement of RSUs (in shares)				241
Stock-based compensation expense	26,328				26,328					26,328
Net unrealized gain on short-term marketable securities	12								12	12
Net loss	(39,318)						(39,318)			(39,318)
Ending balances, Shares at Mar. 31, 2021				137,297
Ending balances at Mar. 31, 2021	481,811			$ 137	884,529		(402,875)		20	481,811
Beginning balances, Shares at Dec. 31, 2020				134,472
Beginning balances at Dec. 31, 2020	548,475			$ 134	918,118		(369,785)		8	548,475
Beginning balances (ASU 2020-06) at Dec. 31, 2020		(66,737)				$ (73,393)		6,656			(66,737)
Beginning balances (ASC 326) at Dec. 31, 2020		$ (428)						$ (428)			$ (428)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized gain on short-term marketable securities	0
Net loss	(80,605)
Ending balances, Shares at Jun. 30, 2021				137,774
Ending balances at Jun. 30, 2021	472,444			$ 138	916,460		(444,162)		8	472,444
Beginning balances, Shares at Mar. 31, 2021				137,297
Beginning balances at Mar. 31, 2021	481,811			$ 137	884,529		(402,875)		20	481,811
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)				353
Exercise of stock options	2,628			$ 1	2,627					2,628
Issuance of common stock under the employee stock purchase plan (in shares)				107
Issuance of common stock under the employee stock purchase plan	2,972				2,972					2,972
Issuance of common stock for settlement of RSUs (in shares)				17
Stock-based compensation expense	26,332				26,332					26,332
Net unrealized gain on short-term marketable securities	(12)								(12)	(12)
Net loss	(41,287)						(41,287)			(41,287)
Ending balances, Shares at Jun. 30, 2021				137,774
Ending balances at Jun. 30, 2021	$ 472,444			$ 138	$ 916,460		$ (444,162)		$ 8	$ 472,444

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
3.0% Convertible Senior Notes due 2025
Stock issuance costs		$ 2,243
IPO
Stock issuance costs	$ 23,631

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (80,605)	$ (64,858)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Provision for bad debts	105	213
Depreciation and amortization	13,899	10,388
Amortization of debt discount and issuance costs	937	1,135
Accretion of discounts and amortization of premiums on short-term investments, net	483	(520)
Change in fair value of redeemable convertible preferred stock warrant liability	0	6,560
Reduction of operating lease right-of-use assets	8,609	6,575
Stock-based compensation	52,660	18,688
Other non-cash items	400	(10)
Changes in operating assets and liabilities:
Accounts receivable, net	11,380	(13,591)
Inventories	3,216	93
Prepaid expenses and other current assets	(21,261)	1,118
Other assets	110	(250)
Accounts payable	1,234	(2,110)
Accrued expenses	6,772	12,893
Deferred revenue	6,765	16,051
Operating lease liabilities	(8,761)	(5,132)
Other liabilities	17,128	2,652
Net cash provided by (used in) operating activities	13,071	(10,105)
Cash flows from investing activities:
Purchases of property and equipment	(31,172)	(39,554)
Purchases of short-term marketable securities	(79,984)	(367,367)
Proceeds from sales and maturities of short-term marketable securities	498,977	123,314
Acquisitions of businesses	(9,695)	0
Issuance of note receivable	(20,000)	0
VIE deconsolidation	0	(810)
Net cash provided by (used in) investing activities	358,126	(284,417)
Cash flows from financing activities:
Proceeds from issuance of convertible senior notes	0	316,250
Payment of convertible senior notes issuance costs	0	(8,756)
Proceeds from initial public offering	0	281,750
Payment of underwriting discount and commissions, and offering costs	0	(21,322)
Proceeds from the exercise of stock options	16,107	2,096
Proceeds from employee stock purchase plan	2,972	0
Proceeds from the exercise of redeemable convertible preferred and common stock warrants	0	110
Repayment of notes payable	0	(2,200)
Payment of principal portion of finance lease liability	(29)	(29)
Net cash provided by financing activities	19,050	567,899
Net increase in cash, cash equivalents and restricted cash	390,247	273,377
Cash, cash equivalents and restricted cash at beginning of period	115,005	29,329
Cash, cash equivalents and restricted cash at end of period	505,252	302,706
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	5,883	3,620
Offering costs included in accounts payable and accrued expenses	0	625
Reimbursement of secondary offering costs in prepaid expenses and other current assets	$ 0	$ 784

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	Nature of the Business and Basis of Presentation 1Life Healthcare, Inc. (“1Life”) was incorporated in Delaware on July 25, 2002. 1Life’s headquarters are located in San Francisco, California. 1Life has developed a modernized healthcare membership model based on direct consumer enrollment as well as employer sponsorship. 1Life is also an administrative and managerial services company that provides services pursuant to contracts with physician-owned professional corporations (“PCs”) or “One Medical Entities” that provide medical services in-office and virtually. 1Life and the One Medical Entities are collectively referred to herein as the “Company” and operate under the brand name One Medical. Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), which include the accounts of 1Life and variable interest entities (“VIE”) in which 1Life has an interest and is the primary beneficiary. See Note 3, “Variable Interest Entities”. Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). All significant intercompany balances and transactions have been eliminated in consolidation. The noncontrolling interest attributable to the Company’s variable interest entities are presented as a separate component of equity in the condensed consolidated balance sheets. In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly state its condensed consolidated financial position, results of operations, comprehensive loss and cash flows. The Company’s interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 as filed with the SEC on March 17, 2021 (the “Form 10-K”). Use of Estimates The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and regulations of the SEC requires management to make estimates and assumptions that affect the amount reported in the condensed consolidated financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, determination of useful lives for property and equipment, intangible assets including goodwill, capitalized internal-use software, allowance for doubtful accounts, self-insurance reserves, valuation of common stock, stock options valuations, convertible senior notes fair value, contingent liabilities and income taxes. Actual results could differ materially from those estimates. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there continues to be a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or an adjustment to the carrying value of its assets or liabilities. The accounting estimates and other matters assessed include, but were not limited to, revenue recognition, allowance for doubtful accounts and goodwill and other long-lived assets. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020. Intended to provide economic relief to those impacted by the COVID-19 pandemic, the CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant from the Provider Relief Fund administered by the Department of Health and Human Services (“HHS”) during the six months ended June 30, 2021. See Note 5, “Revenue Recognition”. Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted of cash on deposit, investments in money market funds and commercial paper. Restricted cash represents cash held under letters of credit for various leases. The expected duration of restrictions on the Company’s restricted cash generally ranges from 1 to 9 years. The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the condensed consolidated statements of cash flows is as follows: June 30, December 31, June 30, December 31, 2021 2020 2020 2019 Cash and cash equivalents $ 503,238 $ 112,975 $ 300,675 $ 27,390 Restricted cash, current (included in prepaid expenses and other current assets) 119 119 17 17 Restricted cash, non-current 1,895 1,911 2,014 1,922 Total cash, cash equivalents, and restricted cash $ 505,252 $ 115,005 $ 302,706 $ 29,329 Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash balances with individual banking institutions might be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company’s marketable securities are invested in U.S. Treasury obligations, U.S. government agency securities, foreign government bonds and commercial paper. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. The Company grants unsecured credit to patients, most of whom reside in the service area of the One Medical facilities and are largely insured under third-party payer agreements. The Company’s concentration of credit risk is limited by the diversity, geography and number of patients and payers. The table below presents the customers that individually represented 10% or more of the Company’s accounts receivable, net balance as of June 30, 2021 and December 31, 2020. June 30, December 31, 2021 2020 Customer A 13 % * Customer E 15 % 12 % Customer F 16 % 24 % Customer H 14 % 16 % * Represents percentages below 10% of the Company’s accounts receivable in the period. The table below presents the customers that individually represented 10% or more of the Company’s net revenue for the three and six months ended June 30, 2021 and 2020. Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Customer A 12 % * 12 % 11 % Customer E * 11 % * 11 % Customer F 12 % 12 % 12 % 12 % * Represents percentages below 10% of the Company’s net revenue in the period.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Other than items discussed under Recently Adopted Pronouncements as of June 30, 2021, there have been no material changes to the Company’s significant accounting policies as discussed in Note 2 “Summary of Significant Accounting Policies” in Item 15 of its Form 10-K for the fiscal year ended December 31, 2020. Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. The Company will cease to be an emerging growth company, as defined in the JOBS Act, at the end of this fiscal year ending December 31, 2021. Recently Adopted Pronouncements as of June 30, 2021 In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, Debt—Debt with Conversion and Other Options , for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted this standard on January 1, 2021 on a modified retrospective basis. Under previous GAAP, instruments that may be partially settled in cash were in the scope of the “cash conversion” model, which required conversion features to be separately reported in equity. Upon the adoption of ASU 2020-06, the cash conversion model was eliminated and the Company no longer separates its convertible senior notes (“the 2025 Notes”) into liability and equity components and instead accounts for the 2025 Notes as a single liability instrument. As a result, there is no longer a debt discount or subsequent amortization to be recognized as interest expense. Further, ASU 2020-06 requires the use of the if-converted method for diluted earnings per share calculation, and no longer allows the use of the treasury stock method for instruments with flexible settlement arrangements. Under the previous treasury stock method, only the excess of the average stock price of the Company’s common stock for the reporting period over the conversion price was used in determining the impact to the diluted earnings per share denominator. Under the current if-converted method, all underlying shares shall be included in the denominator regardless of the average stock price for the reporting period, in addition to adding back to the numerator the related interest expense from the stated coupon and the amortization of issuance costs, if dilutive. The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. Accordingly, the cumulative-effect adjustment to the opening balance of accumulated deficit as of January 1, 2021 was as follows: December 31, 2020 Effect of the Adoption of ASU 2020-06 January 1, 2021 Liabilities Convertible senior notes $ 241,233 $ 66,737 $ 307,970 Stockholders' Equity Additional paid-in capital 918,118 (73,393) 844,725 Accumulated deficit (369,785) 6,656 (363,129) The impact of adoption on the condensed consolidated statements of operations for the three and six months ended June 30, 2021 was primarily a reduction of non-cash interest expense of $3,239 and $6,408, respectively. The reduction in interest expense decreased the net loss attributable to common stockholders and decreased the basic net loss per share. The required use of the if-converted method for earnings per share does not impact the diluted net loss per share as long as the Company is in a net loss position. The adoption had no impact on the condensed consolidated statement of cash flows. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and also issued subsequent amendments to the initial guidance (collectively, Topic 326). Topic 326 replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. Upon adoption of the standard, the Company regularly reviews the adequacy of the allowance for credit losses based on a combination of factors, including historical losses adjusted for current market conditions, the Company's customers' financial condition, delinquency trends, aging behaviors of receivables and credit and liquidity indicators for industry groups, and future market and economic conditions. For available-for-sale debt securities with unrealized losses, the standard limits the amount of credit losses to be recognized to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company early adopted the standard on January 1, 2021 using a modified retrospective approach with no material impact to the condensed consolidated financial statements. The adoption of the standard did not significantly change the Company's approach to the valuation of trade receivables, available-for-sale debt securities or other note receivables. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use-software. The Company adopted the standard on January 1, 2021 on a prospective basis. The adoption did not have a material impact on the Company’s condensed consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted as of June 30, 2021 There have been no recent accounting pronouncements or changes in accounting pronouncements that are of significance or potential significance to the Company as of June 30, 2021.

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities 1Life’s agreements with the PCs generally consist of both Administrative Services Agreements (“ASAs”), which provide for various administrative and management services to be provided by 1Life to the PCs, and Succession Agreements, which provide for transition of ownership of the PCs under certain conditions. The ASAs typically provide that the term of the arrangements is ten years with automatic renewal for successive one-year terms, subject to termination by 1Life or the PC in certain specified circumstances. The outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed by 1Life (or the PC in one instance) under the terms of the Succession Agreements or other shareholders who are also subject to the terms of the Succession Agreements. 1Life has the right to receive income as an ongoing administrative fee in an amount that represents the fair value of services rendered and has provided all financial support through loans to the PCs. 1Life has exclusive responsibility for the provision of all nonmedical services including facilities, technology and intellectual property required for the day-to-day operation and management of each of the PCs, and makes recommendations to the PC in establishing the guidelines for the employment and compensation of the physicians and other employees of the PCs. In addition, the agreements provide that 1Life has the right to designate a person(s) to purchase the stock of the PCs for a nominal amount in the event of a succession event. Based upon the provisions of these agreements, 1Life determined that the PCs are variable interest entities due to its equity holder having insufficient capital at risk, and 1Life has a variable interest in the PCs. The contractual arrangement to provide management services allows 1Life to direct the economic activities that most significantly affect the PC. Accordingly, 1Life is the primary beneficiary of the PCs and consolidates the PCs under the VIE model. Furthermore, as a direct result of nominal initial equity contributions by the physicians, the financial support 1Life provides to the PCs (e.g. loans) and the provisions of the nominee shareholder succession arrangements described above, the interests held by noncontrolling interest holders lack economic substance and do not provide them with the ability to participate in the residual profits or losses generated by the PCs. Therefore, all income and expenses recognized by the PCs are allocated to 1Life stockholders. The aggregate carrying value of the current assets and liabilities included in the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions and balances were $50,843 and $42,792, respectively, as of June 30, 2021 and $48,182 and $31,462, respectively, as of December 31, 2020. The PCs did not have noncurrent assets or liabilities.

Fair Value Measurements and Inv

Fair Value Measurements and Investments	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements and Investments	Fair Value Measurements and Investments Fair Value Measurements The following tables present information about the Company’s financial assets measured at fair value on a recurring basis: Fair Value Measurements as of June 30, 2021 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 470,384 $ — $ — $ 470,384 Short-term investments: U.S. Treasury obligations 60,563 — — 60,563 Foreign government bonds — 5,055 — 5,055 Commercial paper — 84,941 — 84,941 Total financial assets $ 530,947 $ 89,996 $ — $ 620,943 Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 50,761 $ — $ — $ 50,761 Commercial paper — 19,999 — 19,999 Short-term investments: U.S. Treasury obligations 416,158 — — 416,158 U.S. government agency securities 20,000 — — 20,000 Commercial paper — 133,865 — 133,865 Total financial assets $ 486,919 $ 153,864 $ — $ 640,783 During the three and six months ended June 30, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3. Valuation of Convertible Senior Notes The Company has $316,250 aggregate principal amount outstanding of 3.0% convertible senior notes due in 2025 (the “2025 Notes”). Please r efer to Note 9, “Convertible Senior Notes” for further details on the 2025 Notes. The fair value of the 2025 Notes was $351,003 and $397,472 as of June 30, 2021 and December 31, 2020, respectively. The fair value was determined based on the closing trading price of the 2025 Notes as of the last day of trading for the period. The fair value of the 2025 Notes is primarily affected by the trading price of the Company's common stock and market interest rates. The fair value of the 2025 Notes is considered a Level 2 measurement as they are not actively traded. Investments At June 30, 2021 and December 31, 2020, the Company’s cash equivalents and short-term marketable securities were as follows: June 30, 2021 Amortized Gross Fair value Cash equivalents: Money market fund $ 470,384 $ — $ 470,384 Short-term marketable securities: U.S. Treasury obligations 60,553 10 60,563 Foreign government bonds 5,056 (1) 5,055 Commercial paper 84,941 — 84,941 Total short-term marketable securities 150,550 9 150,559 Total cash equivalents and short-term marketable securities $ 620,934 $ 9 $ 620,943 December 31, 2020 Amortized Gross Fair value Cash equivalents: Money market fund $ 50,761 $ — $ 50,761 Commercial paper 19,999 — 19,999 Total cash equivalents 70,760 — 70,760 Short-term marketable securities: U.S. Treasury obligations 416,150 8 416,158 U.S. government agency securities 20,000 — 20,000 Commercial paper 133,865 — 133,865 Total short-term marketable securities 570,015 8 570,023 Total cash equivalents and short-term marketable securities $ 640,775 $ 8 $ 640,783

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The following table summarizes the Company’s net revenue by primary source: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net revenue: Net patient service revenue $ 43,416 $ 23,927 $ 87,878 $ 58,013 Partnership revenue 56,126 33,993 111,057 63,448 Total net patient service and partnership revenue 99,542 57,920 198,935 121,461 Membership revenue 20,874 17,680 41,070 32,895 Grant income — 2,400 1,763 2,400 Net revenue $ 120,416 $ 78,000 $ 241,768 $ 156,756 Net patient service revenue is primarily generated from commercial third-party payers with which the One Medical entities have established contractual billing arrangements. The following table summarizes net patient service revenue by source: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net patient service revenue: Commercial and government third-party payers $ 39,608 $ 20,985 $ 81,843 $ 50,876 Patients, including self-pay, insurance co-pays and deductibles 3,808 2,942 6,035 7,137 Net patient service revenue $ 43,416 $ 23,927 $ 87,878 $ 58,013 The CARES Act was enacted on March 27, 2020 to provide economic relief to those impacted by the COVID-19 pandemic. The CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant of $1,763 from the Provider Relief Fund administered by the Health and Human Services ("HHS") during the six months ended June 30, 2021. The Company received an income grant of $2,400 during the three and six months ended June 30, 2020. The Company did not receive any income grants from the HHS for the three months ended June 30, 2021. Management has concluded that the Company met conditions of the grant funds and has recognized it as Grant income for the six months ended June 30, 2021 and June 30, 2020, respectively. During the three and six months ended June 30, 2021, the Company recognized revenue of $20,041 and $26,187 respectively, which was included in the beginning deferred revenue balances as of April 1, 2021 and January 1, 2021, respectively. During the three and six months ended June 30, 2020, the Company recognized revenue of $15,995 and $17,458, respectively, which was included in the beginning deferred revenue balances as of April 1, 2020 and January 1, 2020, respectively. As of June 30, 2021, a total of $6,356 is included within deferred revenue related to variable consideration, of which $5,351 is classified as non-current as it will not be recognized within the next twelve months. The estimate of variable consideration is based on the Company’s assessment of historical, current, and forecasted performance. As summarized in the table below, the Company recorded contract assets and deferred revenue as a result of timing differences between the Company’s performance and the customer’s payment. June 30, December 31, 2021 2020 Balances from contracts with customers: Accounts receivable $ 55,982 $ 67,895 Contract asset (included in prepaid expenses and other current assets) 788 513 Deferred revenue 50,355 43,590 The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. For those contracts that do not meet the above criteria, the Company’s remaining performance obligation as of June 30, 2021, is expected to be recognized as follows: Less than Greater Total As of June 30, 2021 $ 4,676 $ 9,186 $ 13,862

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Leases	LeasesMost leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 7 years. Certain lease agreements contain options to terminate the lease before maturity. The Company does not have any lease contracts with the option to purchase as of June 30, 2021. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases. Certain of the Company’s furniture and fixtures and lab equipment are held under finance leases. Lease-related assets are included in property and equipment, net in the condensed consolidated balance sheets and are immaterial as of June 30, 2021. The components of operating lease costs were as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease costs $ 7,856 $ 6,355 $ 15,189 $ 12,315 Variable lease costs 1,222 1,013 2,533 2,029 Total lease costs $ 9,078 $ 7,368 $ 17,722 $ 14,344 Other information related to leases was as follows: Supplemental Cash Flow Information Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 7,973 $ 5,920 $ 15,828 $ 11,358 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 19,336 $ 7,031 $ 35,422 $ 30,638 Lease Term and Discount Rate June 30, December 31, 2021 2020 Weighted-average remaining lease term (in years) 8.47 8.36 Weighted-average discount rate 7.17 % 7.60 % At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate. Management determines the appropriate incremental borrowing rates for each of its leases based on the remaining lease term at lease commencement. Future minimum lease payments under non-cancellable operating leases as of June 30, 2021 were as follows (excluding the effect of lease incentives to be received that are recorded in prepaid expenses and other current assets of $7,697 which serve to reduce total lease payments): June 30, 2021 Remainder of 2021 $ 17,310 2022 34,120 2023 33,150 2024 31,899 2025 29,994 Thereafter 127,922 Total lease payments 274,395 Less: interest (71,787) Total lease liabilities $ 202,608

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business Combinations Completed Business Combinations During the three months ended June 30, 2021, the Company completed two acquisitions for $9,350 of total cash consideration. The acquisitions were each accounted for as a business combination. The Company does not consider these acquisitions to be material, individually or in aggregate, to the Company’s unaudited condensed consolidated financial statements. The preliminary purchase price allocations resulted in $5,565 of goodwill and $3,700 of acquired identifiable intangible assets related to customer relationships valued using the income method. Intangible assets are presented in other assets in the condensed consolidated balance sheets and are being amortized over their respective useful lives of seven years. Acquisition-related costs were immaterial and were expensed as incurred in the condensed consolidated statements of operations. Proposed Business Combination On June 6, 2021, 1Life entered into a definitive agreement to acquire Iora Health, Inc. (“Iora”) pursuant to an Agreement and Plan of Merger (the “Merger Agreement”). Iora is a human-centered, value-based primary care group with built-for-purpose technology focused on serving Medicare populations. Pursuant to the terms of the Merger Agreement, at the closing of the proposed transaction, each outstanding share of Iora capital stock will be converted into the right to receive approximately 0.689 shares of 1Life's common stock, and 1Life will assume outstanding and unexercised options to purchase Iora common stock, will be converted into options to purchase shares of 1Life’s common stock at the same ratio . The total number of shares of 1Life's common stock to be issued or reserved for issuance will be approximately 56,100 shares. Based on the number of shares of 1Life common stock and Iora capital stock outstanding on July 13, 2021, upon the completion of the merger, current 1Life stockholders and former Iora stockholders are expected to own approximately 78% and 22% of the combined company, respectively. The Merger Agreement contains certain customary termination rights for both parties and provides that, in connection with a termination of the Merger Agreement under certain specified circumstances, (a) 1Life will pay Iora a termination fee of $50,000 or a termination fee equal to all reasonable out-of-pocket fees and expenses actually incurred by Iora in connection with the transactions, up to a maximum of $10,000, or (b) Iora will pay 1Life a termination fee of $50,000. During the six months ended June 30, 2021, the Company incurred approximately $11,148 in expenses related to this proposed transaction. The completion of the merger is subject to customary conditions to closing, including stockholder and regulatory approval. The Company expects the transaction to close in the third quarter of 2021.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill As of June 30, 2021 and December 31, 2020, goodwill was $26,866 and $21,301, respectively. During the three and six months ended June 30, 2021, the Company recorded $5,565 of goodwill in connection with the acquisitions that were completed during the three months ended June 30, 2021. See Note 7 "Business Combinations". No goodwill impairments were recorded during the three and six months ended June 30, 2021. Goodwill balances as of June 30, 2021 and December 31, 2020 were as follows: Goodwill Balance as of December 31, 2020 $ 21,301 Goodwill recorded in connection with acquisitions 5,565 Balance as of June 30, 2021 $ 26,866 Intangible Assets During the three and six months ended June 30, 2021, the Company recorded $3,700 of intangible assets related to acquisitions. See Note 7 "Business Combinations". Amortization expense of intangible assets for the three and six months ended June 30, 2021 was immaterial. The Company had no intangible assets as of December 31, 2020 and did not record any amortization expense of intangible assets for the three and six months ended June 30, 2020. The following summarizes the Company’s intangible assets and accumulated amortization as of June 30, 2021: June 30, 2021 Original Cost Accumulated Amortization Net Book Value Customer relationships $ 3,700 $ (88) $ 3,612 Total intangible assets $ 3,700 $ (88) $ 3,612 As of June 30, 2021, estimated future amortization expense related to intangible assets were as follows: June 30, 2021 Remainder of 2021 $ 264 2022 529 2023 529 2024 529 2025 529 Thereafter 1,320 Total $ 3,700

Convertible Senior Notes

Convertible Senior Notes	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Convertible Senior Notes	Convertible Senior Notes In May 2020, the Company issued and sold $275,000 aggregate principal amount of 3.0% convertible senior notes due 2025 in a private offering exempt from the registration requirements of the Securities Act of 1933, and in June 2020, the Company issued an additional $41,250 aggregate principal amount of such notes pursuant to the exercise in full of the over-allotment option by the initial purchasers of the notes (the “2025 Notes”). The 2025 Notes are unsecured obligations and bear interest at a fixed rate of 3.0% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2020. The 2025 Notes will mature on June 15, 2025, unless earlier converted, redeemed or repurchased. The total net proceeds from the debt offering, after deducting the initial purchasers’ commissions and other issuance costs, were $306,868. Each $1 principal amount of the 2025 Notes will initially be convertible into 22.5052 shares of the Company’s common stock, which is equivalent to an initial conversion price of $44.43 per share, subject to adjustment upon the occurrence of specified events but not for any accrued and unpaid interest. Holders may convert the 2025 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined below) per $1 principal amount of the 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls such 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. It is the Company’s current intent to settle conversions through combination settlement consisting of cash and equity. On or after March 15, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their 2025 Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election and in accordance with the terms of the indenture governing the 2025 Notes. If the Company satisfies its conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company’s common stock, the amount of cash and shares of common stock, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 40 trading day observation period. In addition, following certain corporate events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2025 Notes in connection with such a corporate event or notice of redemption, as the case may be. If the Company undergoes a fundamental change prior to the maturity date, holders of the 2025 Notes may require the Company to repurchase for cash all or any portion of their notes at a repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if specific corporate events occur prior to the applicable maturity date, the Company will increase the conversion rate for a holder who elects to convert their 2025 Notes in connection with such a corporate event in certain circumstances. The Company may not redeem the 2025 Notes prior to June 20, 2023. The Company may redeem for cash all or any portion of the 2025 Notes, at the Company’s option, on or after June 20, 2023 and prior to March 15, 2025, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the notes. During the three months ended June 30, 2021, the conditions allowing holders of the 2025 Notes to convert have not been met. The 2025 Notes are therefore not convertible as of June 30, 2021 and are classified in long term liabilities in the condensed consolidated balance sheet. The Company adopted ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), ("ASU 2020-06"), as of January 1, 2021. Under ASU 2020-06, the Company is no longer required to bifurcate the equity component from the liability component for the 2025 Notes and instead accounts for it as a single liability instrument. Comparative prior period consolidated financial statements have not been restated for ASU 2020-06 and are not directly comparable to the current period condensed consolidated financial statements. See Note 2 "Summary of Significant Accounting Policies" for details on adoption impact. The Company incurred issuance costs of $9,374 and amortizes the issuance costs to interest expense over the contractual term of the 2025 Notes at an effective interest rate of 0.65%. The net carrying amount of the 2025 Notes was as follows: June 30, 2021 Liabilities: Principal $ 316,250 Unamortized issuance costs (7,343) Net carrying amount $ 308,907 The following table sets forth the interest expense recognized related to the 2025 Notes: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Contractual interest expense $ 2,372 $ 826 $ 4,744 $ 826 Amortization of debt discount — 1,041 — 1,041 Amortization of issuance costs 468 79 937 79 Total interest expense related to the 2025 Notes $ 2,840 $ 1,946 $ 5,681 $ 1,946

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock Incentive Plan The Company has the following stock-based compensation plans: the 2007 Equity Incentive Plan (the “2007 Plan”), the 2017 Equity Incentive Plan (the “2017 Plan”), and the 2020 Equity Incentive Plan (the “2020 Plan”, and, together with the 2007 Plan and the 2017 Plan, the “Plans”). In January 2020, the Company’s stockholders approved the 2020 Plan, which took effect upon the execution of the underwriting agreement for the Company’s IPO in January 2020. The 2020 Plan is intended as the successor to and continuation of the 2007 Plan and the 2017 Plan. No additional stock awards will be granted under these prior plans. The number of shares of common stock reserved for issuance under the Company’s 2020 Plan will automatically increase on January 1 of each year, beginning on January 1, 2021, and continuing through and including January 1, 2030, by 4% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company’s board prior to the applicable January 1st. The number of shares issuable under the Plans is adjusted for capitalization changes, forfeitures, expirations and certain share reacquisitions. The Plan provides for the grants of incentive stock options (“ISOs”), nonstatutory stock options (“NSOs”), restricted stock awards, and restricted stock unit awards (“RSUs”). ISOs may be granted only to employees, including officers. All other awards may be granted to employees, including officers, non-employee directors and consultants. The 2020 Plan provides that grants of ISOs will be made at no less than the estimated fair value of common stock, as determined by the Board of Directors, at the date of grant. Stock options granted to employees and nonemployees under the Plans generally vest over four years. Options granted under the Plans generally expire ten years after the date of grant. At June 30, 2021, 11,346 shares were available for future grants. 2020 Employee Stock Purchase Plan In January 2020, the Company’s stockholders approved the 2020 Employee Stock Purchase Plan (the “ESPP”) . The 2020 ESPP became effective upon the execution of the underwriting agreement for the Company’s IPO in January 2020. The Company had initially reserved 2,800 shares of common stock for issuance under the 2020 ESPP. Effective as of January 1, 2021, an additional 2,017 shares of common stock became available for issuance under the ESPP, as a result of the operation of an automatic annual increase provision therein. At June 30, 2021, 4,361 shares were available for future issuance. The initial offering period ran from January 31, 2020 to August 15, 2020 and the second offering period ran from August 16, 2020 to November 15, 2020. For subsequent periods, the ESPP will provide for separate six-month offering periods beginning on May 16 and November 16 of each year. During the three months ended June 30, 2021, the Company’s employees purchased approximately 107 shares under the ESPP at a weighted-average price of $27.85 per share. The stock-based compensation expense recognized for the ESPP was $591 and $1,212 during the three and six months ended June 30, 2021 and $597 and $1,006 during the three and six months ended June 30, 2020, respectively. Stock Options The following table summarizes stock option activity under the 2020 Plan: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2020 28,273 $ 18.03 8.20 $ 724,339 Granted 545 42.68 Exercised (2,937) 5.48 Canceled (127) 8.37 Outstanding as of June 30, 2021 25,754 $ 20.03 7.90 $ 429,423 Options exercisable as of June 30, 2021 8,807 $ 5.77 6.48 $ 240,961 Options vested and expected to vest as of June 30, 2021 15,291 $ 20.62 7.89 $ 390,516 At June 30, 2021 and 2020, there was $14,805 and $32,690, respectively, in unrecognized compensation expense related to service-based options, net of forfeitures, that is expected to be recognized over a weighted-average period of 1.8 years and 2.0 years, respectively. The fair value of stock option grants with service-based vesting conditions was $50 and $12,218 for the three and six months ended June 30, 2021, and $3,180 and $4,429, respectively, for the three and six months ended June 30, 2020. Market-based Stock Options During the year ended December 31, 2020, the Board of Directors (“Board”) approved the grant of a long-term market-based stock option (the “Performance Stock Option”) to the Company’s Chief Executive Officer and President. The Performance Stock Option was granted to acquire up to 8,645 shares of the Company’s common stock upon exercise. The Performance Stock Option consists of four separate tranches and each tranche will vest over a seven-year time period and only if the Company’s stock price sustains achievement of pre-determined increases for a period of 90 consecutive calendar days and the Chief Executive Officer remains employed with the Company. The exercise price per share of the Stock Option is the closing price of a share of the Company’s common stock on the date of grant. The vesting of the Performance Stock Option can also be triggered upon a change in control. The following table presents additional information relating to each tranche of the Performance Stock Option: Tranche Stock Price Milestone Number of Options Tranche 1 $55 per share 1,330 Tranche 2 $70 per share 1,995 Tranche 3 $90 per share 2,660 Tranche 4 $110 per share 2,660 As of June 30, 2021, no stock price milestones have been achieved. Consequently, no shares subject to the Performance Stock Option have vested as of the date of this filing. The entire 8,645 shares granted are excluded from options vested and expected to vest from the options activity table presented above. The Company will recognize aggregate stock-based compensation expense of $197,469 over the derived service period of each tranche using the accelerated attribution method as long as the service-based vesting conditions are satisfied. If the market conditions are achieved sooner than the derived service period, the Company will adjust its stock-based compensation to reflect the cumula tive expense associated with the vested awards. The Company recorded stock-based compensation expense of $14,924 and $29,850 related to the award for the three and six months ended June 30, 2021, which is included in general and administrative on the condensed consolidated statements of operations. Unamortized stock-based compensation expense related to the award was $167,128 as of June 30, 2021. Restricted Stock Units The following table summarizes restricted stock unit activity under the 2020 Plan: Number of Grant Date Unvested and outstanding as of December 31, 2020 1,291 $ 22.14 Granted 1,170 42.00 Vested (258) 22.54 Canceled and forfeited (150) 28.55 Unvested and outstanding as of June 30, 2021 2,053 $ 32.94 Stock-Based Compensation Expense Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Sales and marketing $ 964 $ 668 $ 1,987 $ 1,268 General and administrative 25,368 7,695 50,673 17,420 Total $ 26,332 $ 8,363 $ 52,660 $ 18,688 A tax benefit of $2,248 and $32,642 for the three and six months ended June 30, 2021, respectively, and $92 and $372 for the three and six months ended June 30, 2020, respectively, was included in the Company’s net operating loss carry-forward that could potentially reduce future tax liabilities.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe Company recorded an income tax benefit of $4,040 and $22 to operations for the three months ended June 30, 2021 and June 30, 2020, respectively. This represents an effective tax rate for the respective periods of 8.913% and 0.075%, respectively. The Company reassessed the ability to realize deferred tax assets by considering the available positive and negative evidence. As of June 30, 2021, the Company maintains a partial valuation allowance against its net deferred tax assets. The effective tax rate differs in 2021 and 2020 from the federal statutory rate due to the change in need for valuation allowance. The Company recorded an income tax provision of $159 and benefit of $72 to operations for the six months ended June 30, 2021 and June 30, 2020, respectively. This represents an effective tax rate for the respective periods of (0.198)% and 0.124%, respectively. The Company reassessed the ability to realize deferred tax assets by considering the available positive and negative evidence. As of June 30, 2021, the Company maintains a partial valuation allowance against its net deferred tax assets. The effective tax rate differs in 2021 and 2020 from the federal statutory rate due to the change in need for valuation allowance.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Net Loss Per Share Attributable to 1Life Healthcare, Inc. Stockholders Basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders were calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Numerator: Net loss $ (41,287) $ (30,301) $ (80,605) $ (64,858) Less: Net loss attributable to noncontrolling interest — — — (704) Net loss attributable to 1Life Healthcare, Inc. stockholders $ (41,287) $ (30,301) $ (80,605) $ (64,154) Denominator: Weighted average common shares outstanding — basic and diluted 136,788 126,150 137,045 105,517 Net loss per share attributable to 1Life Healthcare, Inc. stockholders — basic and diluted $ (0.30) $ (0.24) $ (0.59) $ (0.61) The Company’s potentially dilutive securities, which include stock options, unvested RSUs, 2025 Notes, redeemable convertible preferred stock and warrants to purchase shares of redeemable convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of June 30, 2021 2020 Options to purchase common stock 25,754 27,636 Unvested restricted stock 2,053 1,320 Warrants to purchase common stock — 162 2025 Notes (1) 7,117 — 34,924 29,118

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. As of June 30, 2021 and December 31, 2020, the Company has not incurred any material costs as a result of such indemnifications. Legal Matters In May 2018, a class action complaint was filed by two former members against the Company in the Superior Court of California for the County of San Francisco, or the Court, alleging that the Company made certain misrepresentations resulting in them paying the Annual Membership Fee, or AMF, in violation of California’s Consumers Legal Remedies Act, California’s False Advertising Law and California’s Unfair Competition Law, and seeking damages and injunctive relief. Following trial proceedings and certain appeals and court-ordered mediation proceedings, in June 2021, the parties filed a joint notice of settlement and request for a six month stay in light of reaching a settlement agreement. The parties later executed a class action settlement agreement and release effective June 30, 2021 and a preliminary class settlement approval hearing has been scheduled to take place in August 2021. The settlement amount of $11,500 is recorded as other current liabilities in the condensed consolidated balance sheets as of June 30, 2021. In addition, the Company's insurers committed to pay $5,950 towards the settlement amount. Because recovery from the insurers is probable, a receivable is also recorded for $5,950 as prepaid expenses and other current assets in the condensed consolidated balance sheets as of June 30, 2021. The settlement amount, net of expected insurance recovery, of $5,550 is recorded as general and administrative expenses in the condensed consolidated statements of operations for the three months ended June 30, 2021. Stockholder Litigation Related to Iora Health Acquisition On July 15, 2021, Gary Kosman, a purported stockholder in the Company, filed a complaint in the United States District Court for the Northern District of California, against the Company and its board of directors. The case is captioned Gary Kosman v. 1Life Healthcare, Inc. et al.. On July 19, 2021, Matthew Hopkins, a purported stockholder in 1Life, filed a complaint in the United States District Court for the Southern District of New York against the Company, its board of directors, SB Merger Sub, Inc., and Iora Health, Inc. The case is captioned Matthew Hopkins v. 1Life Healthcare, Inc. et al.. On July 27, 2021, Angel Rodriguez, a purported stockholder in 1Life, filed a complaint in the United States District Court for the Eastern District of New York against the Company and its board of directors. The three complaints allege, among other things, that the disclosures in the Company’s registration statement on Form S-4 regarding the proposed merger are materially misleading and that the defendants therefore violated Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Each plaintiff seeks, among other things, injunctive relief, including enjoining the proposed merger, and attorney’s fees and costs. Each plaintiff also seeks rescission of the merger or rescissory damages if the proposed merger is completed and an order directing the individual defendants to disseminate a registration statement that does not contain untrue statements of material fact and states all material facts required to make the statements contained therein not misleading. Additional lawsuits may be filed against the Company or its directors and officers in connection with the merger. Defending such lawsuits could require the Company to incur significant costs and divert the attention of the management team. Further, the defense or settlement of any lawsuit or claim that remains unresolved at the closing of the proposed merger may adversely affect the Company's business, financial condition, results of operations and cash flows. Such legal proceedings could delay or prevent the closing of the proposed merger from occurring within the contemplated timeframe. The Company cannot predict the outcome of the lawsuits or any others that might be filed subsequent to the date of filing of this Quarterly Report on Form 10-Q and cannot reasonably estimate the possible loss or range of loss with respect to these matters. The Company believes that the lawsuits are without merit and intends to defend against the claims vigorously. Government Inquiries and Investigations In March 2021, the Company received (i) requests for information and documents from the United States House Select Subcommittee on the Coronavirus Crisis, (ii) a request for information from the California Attorney General and the Alameda County District Attorney’s Office and (iii) a request for information and documents from the Federal Trade Commission relating to the Company’s provision of COVID-19 vaccinations. The Company has also received inquiries from state and local public health departments regarding its vaccine administration practices and may continue to receive additional requests for information from other governmental agencies relating to its provision of COVID-19 vaccinations. The Company is cooperating with these requests as well as requests received from other governmental agencies, including with respect to the Company's compensation practices and membership generation during the relevant periods. The Company is unable to predict the outcome or timeline of these matters at this time or if any additional requests, inquiries, investigations or other government actions may arise relating to such circumstances. Legal fees have been recorded as general and administrative expenses in the condensed consolidated statements of operations. Sales and Use Tax During 2017 and 2018, a state jurisdiction engaged in an audit of 1Life’s sales and use tax records applicable to that jurisdiction from March 2011 through February 2017. As of June 30, 2021, the Company estimated a probable loss from the audit and recorded the estimate in accrued expenses related to one aspect of the finding, including interest and penalties. The Company disputes the other finding representing the majority of the state’s proposed audit change and has filed a notice of appeal. An administrative law judge with the state’s tax division conducted a hearing on the appeal in October 2020. A decision from the judge is expected to be issued in the second half of 2021. At this time, the Company believes it has a compelling basis to dispute the audit finding and it is not able to estimate the amount of loss or range of loss, if any, related to this matter. In addition, from time to time, the Company has been and may be involved in various legal proceedings arising in the ordinary course of business. The Company currently believes that the outcome of these legal proceedings, either individually or in the aggregate, will not have a material effect on its condensed consolidated financial position, results of operations or cash flows.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Certain of the Company’s investors are also affiliated with customers of the Company. Revenue recognized under contractual obligations from such customers was immaterial for the three and six months ended June 30, 2021 and June 30, 2020. The outstanding receivable balance from such customers was immaterial as of June 30, 2021 and December 31, 2020, respectively .

Note Receivable

Note Receivable	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Note Receivable	Note Receivable In connection with the proposed merger, on June 21, 2021, the Company and Iora have entered into a loan arrangement under which the Company may advance secured loans to Iora to fund working capital, at Iora’s request from time to time, in outstanding amounts not to exceed $75,000 in the aggregate. Amounts drawn under the loan agreement are secured by all assets of Iora and are subordinated to Iora’s obligations outstanding under its existing credit facility with Silicon Valley Bank ("SVB"). The loan agreement is effective through the earlier of 30 calendar days following any termination of the merger agreement prior to the consummation of the merger ("merger termination"), and the maturity date of borrowed amounts under the loan agreement. Such maturity date is the later of (i) 18 months following any merger termination and (ii) 90 days following the earliest of certain maturity dates set forth in the SVB Facility. Amounts drawn bear interest at a rate equal to 10% per year, payable monthly. Following a merger termination, the interest rate on outstanding drawn amounts will increase by 5% on the six-month anniversary of the termination date and by another 5% on the 12-month anniversary of the termination date, with the total interest rate capped at 20%. Following the merger termination, accrued and unpaid interest will accrete into outstanding principal at the end of each fiscal quarter unless Iora elects to pay such amounts in cash. Interest receivable as of June 30, 2021 was immaterial. The loan agreement includes certain customary covenants and events of default generally consistent with those in the SVB Facility. Iora may voluntarily prepay any drawn amounts under the loan agreement without premium or penalty to the extent permitted under the SVB Facility.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), which include the accounts of 1Life and variable interest entities (“VIE”) in which 1Life has an interest and is the primary beneficiary. See Note 3, “Variable Interest Entities”. Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). All significant intercompany balances and transactions have been eliminated in consolidation. The noncontrolling interest attributable to the Company’s variable interest entities are presented as a separate component of equity in the condensed consolidated balance sheets. In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly state its condensed consolidated financial position, results of operations, comprehensive loss and cash flows. The Company’s interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 as filed with the SEC on March 17, 2021 (the “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and regulations of the SEC requires management to make estimates and assumptions that affect the amount reported in the condensed consolidated financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, determination of useful lives for property and equipment, intangible assets including goodwill, capitalized internal-use software, allowance for doubtful accounts, self-insurance reserves, valuation of common stock, stock options valuations, convertible senior notes fair value, contingent liabilities and income taxes. Actual results could differ materially from those estimates. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there continues to be a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or an adjustment to the carrying value of its assets or liabilities. The accounting estimates and other matters assessed include, but were not limited to, revenue recognition, allowance for doubtful accounts and goodwill and other long-lived assets. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020. Intended to provide economic relief to those impacted by the COVID-19 pandemic, the CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant from the Provider Relief Fund administered by the Department of Health and Human Services (“HHS”) during the six months ended June 30, 2021. See Note 5, “Revenue Recognition”.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted of cash on deposit, investments in money market funds and commercial paper. Restricted cash
Concentration of Credit Risk and Significant Customers	Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash balances with individual banking institutions might be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company’s marketable securities are invested in U.S. Treasury obligations, U.S. government agency securities, foreign government bonds and commercial paper. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. The Company grants unsecured credit to patients, most of whom reside in the service area of the One Medical facilities and are largely insured under third-party payer agreements. The Company’s concentration of credit risk is limited by the diversity, geography and number of patients and payers.
Emerging Growth Company Status	Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. The Company will cease to be an emerging growth company, as defined in the JOBS Act, at the end of this fiscal year ending December 31, 2021.
Recently Adopted Pronouncements as of June 30, 2021	Recently Adopted Pronouncements as of June 30, 2021 In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, Debt—Debt with Conversion and Other Options , for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted this standard on January 1, 2021 on a modified retrospective basis. Under previous GAAP, instruments that may be partially settled in cash were in the scope of the “cash conversion” model, which required conversion features to be separately reported in equity. Upon the adoption of ASU 2020-06, the cash conversion model was eliminated and the Company no longer separates its convertible senior notes (“the 2025 Notes”) into liability and equity components and instead accounts for the 2025 Notes as a single liability instrument. As a result, there is no longer a debt discount or subsequent amortization to be recognized as interest expense. Further, ASU 2020-06 requires the use of the if-converted method for diluted earnings per share calculation, and no longer allows the use of the treasury stock method for instruments with flexible settlement arrangements. Under the previous treasury stock method, only the excess of the average stock price of the Company’s common stock for the reporting period over the conversion price was used in determining the impact to the diluted earnings per share denominator. Under the current if-converted method, all underlying shares shall be included in the denominator regardless of the average stock price for the reporting period, in addition to adding back to the numerator the related interest expense from the stated coupon and the amortization of issuance costs, if dilutive. The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. Accordingly, the cumulative-effect adjustment to the opening balance of accumulated deficit as of January 1, 2021 was as follows: December 31, 2020 Effect of the Adoption of ASU 2020-06 January 1, 2021 Liabilities Convertible senior notes $ 241,233 $ 66,737 $ 307,970 Stockholders' Equity Additional paid-in capital 918,118 (73,393) 844,725 Accumulated deficit (369,785) 6,656 (363,129) The impact of adoption on the condensed consolidated statements of operations for the three and six months ended June 30, 2021 was primarily a reduction of non-cash interest expense of $3,239 and $6,408, respectively. The reduction in interest expense decreased the net loss attributable to common stockholders and decreased the basic net loss per share. The required use of the if-converted method for earnings per share does not impact the diluted net loss per share as long as the Company is in a net loss position. The adoption had no impact on the condensed consolidated statement of cash flows. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and also issued subsequent amendments to the initial guidance (collectively, Topic 326). Topic 326 replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. Upon adoption of the standard, the Company regularly reviews the adequacy of the allowance for credit losses based on a combination of factors, including historical losses adjusted for current market conditions, the Company's customers' financial condition, delinquency trends, aging behaviors of receivables and credit and liquidity indicators for industry groups, and future market and economic conditions. For available-for-sale debt securities with unrealized losses, the standard limits the amount of credit losses to be recognized to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company early adopted the standard on January 1, 2021 using a modified retrospective approach with no material impact to the condensed consolidated financial statements. The adoption of the standard did not significantly change the Company's approach to the valuation of trade receivables, available-for-sale debt securities or other note receivables. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use-software. The Company adopted the standard on January 1, 2021 on a prospective basis. The adoption did not have a material impact on the Company’s condensed consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted as of June 30, 2021	Recently Issued Accounting Pronouncements Not Yet Adopted as of June 30, 2021 There have been no recent accounting pronouncements or changes in accounting pronouncements that are of significance or potential significance to the Company as of June 30, 2021.

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reconciliation of Cash, Cash Equivalents and Restricted Cash	The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the condensed consolidated statements of cash flows is as follows: June 30, December 31, June 30, December 31, 2021 2020 2020 2019 Cash and cash equivalents $ 503,238 $ 112,975 $ 300,675 $ 27,390 Restricted cash, current (included in prepaid expenses and other current assets) 119 119 17 17 Restricted cash, non-current 1,895 1,911 2,014 1,922 Total cash, cash equivalents, and restricted cash $ 505,252 $ 115,005 $ 302,706 $ 29,329
Summary of Customers Representing 10% or More of Accounts Receivables	The table below presents the customers that individually represented 10% or more of the Company’s accounts receivable, net balance as of June 30, 2021 and December 31, 2020. June 30, December 31, 2021 2020 Customer A 13 % * Customer E 15 % 12 % Customer F 16 % 24 % Customer H 14 % 16 % * Represents percentages below 10% of the Company’s accounts receivable in the period.
Summary of Customers Representing 10% or More of Net Revenue	The table below presents the customers that individually represented 10% or more of the Company’s net revenue for the three and six months ended June 30, 2021 and 2020. Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Customer A 12 % * 12 % 11 % Customer E * 11 % * 11 % Customer F 12 % 12 % 12 % 12 % * Represents percentages below 10% of the Company’s net revenue in the period.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Cumulative-effect Adjustment to Opening Balance of Accumulated Deficit	Accordingly, the cumulative-effect adjustment to the opening balance of accumulated deficit as of January 1, 2021 was as follows: December 31, 2020 Effect of the Adoption of ASU 2020-06 January 1, 2021 Liabilities Convertible senior notes $ 241,233 $ 66,737 $ 307,970 Stockholders' Equity Additional paid-in capital 918,118 (73,393) 844,725 Accumulated deficit (369,785) 6,656 (363,129)

Fair Value Measurements and I_2

Fair Value Measurements and Investments (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis: Fair Value Measurements as of June 30, 2021 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 470,384 $ — $ — $ 470,384 Short-term investments: U.S. Treasury obligations 60,563 — — 60,563 Foreign government bonds — 5,055 — 5,055 Commercial paper — 84,941 — 84,941 Total financial assets $ 530,947 $ 89,996 $ — $ 620,943 Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market fund $ 50,761 $ — $ — $ 50,761 Commercial paper — 19,999 — 19,999 Short-term investments: U.S. Treasury obligations 416,158 — — 416,158 U.S. government agency securities 20,000 — — 20,000 Commercial paper — 133,865 — 133,865 Total financial assets $ 486,919 $ 153,864 $ — $ 640,783
Components of Cash Equivalents and Short-term Marketable Securities	At June 30, 2021 and December 31, 2020, the Company’s cash equivalents and short-term marketable securities were as follows: June 30, 2021 Amortized Gross Fair value Cash equivalents: Money market fund $ 470,384 $ — $ 470,384 Short-term marketable securities: U.S. Treasury obligations 60,553 10 60,563 Foreign government bonds 5,056 (1) 5,055 Commercial paper 84,941 — 84,941 Total short-term marketable securities 150,550 9 150,559 Total cash equivalents and short-term marketable securities $ 620,934 $ 9 $ 620,943 December 31, 2020 Amortized Gross Fair value Cash equivalents: Money market fund $ 50,761 $ — $ 50,761 Commercial paper 19,999 — 19,999 Total cash equivalents 70,760 — 70,760 Short-term marketable securities: U.S. Treasury obligations 416,150 8 416,158 U.S. government agency securities 20,000 — 20,000 Commercial paper 133,865 — 133,865 Total short-term marketable securities 570,015 8 570,023 Total cash equivalents and short-term marketable securities $ 640,775 $ 8 $ 640,783

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Summary of Net Revenue	The following table summarizes the Company’s net revenue by primary source: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net revenue: Net patient service revenue $ 43,416 $ 23,927 $ 87,878 $ 58,013 Partnership revenue 56,126 33,993 111,057 63,448 Total net patient service and partnership revenue 99,542 57,920 198,935 121,461 Membership revenue 20,874 17,680 41,070 32,895 Grant income — 2,400 1,763 2,400 Net revenue $ 120,416 $ 78,000 $ 241,768 $ 156,756
Summary of Net Patient Service Revenue by Source	The following table summarizes net patient service revenue by source: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net patient service revenue: Commercial and government third-party payers $ 39,608 $ 20,985 $ 81,843 $ 50,876 Patients, including self-pay, insurance co-pays and deductibles 3,808 2,942 6,035 7,137 Net patient service revenue $ 43,416 $ 23,927 $ 87,878 $ 58,013
Schedule of Contract Assets and Deferred Revenue	As summarized in the table below, the Company recorded contract assets and deferred revenue as a result of timing differences between the Company’s performance and the customer’s payment. June 30, December 31, 2021 2020 Balances from contracts with customers: Accounts receivable $ 55,982 $ 67,895 Contract asset (included in prepaid expenses and other current assets) 788 513 Deferred revenue 50,355 43,590
Schedule of Remaining Performance Obligation	For those contracts that do not meet the above criteria, the Company’s remaining performance obligation as of June 30, 2021, is expected to be recognized as follows: Less than Greater Total As of June 30, 2021 $ 4,676 $ 9,186 $ 13,862

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Components of Operating Lease Costs	The components of operating lease costs were as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease costs $ 7,856 $ 6,355 $ 15,189 $ 12,315 Variable lease costs 1,222 1,013 2,533 2,029 Total lease costs $ 9,078 $ 7,368 $ 17,722 $ 14,344
Supplemental Cash Flow Information	Supplemental Cash Flow Information Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 7,973 $ 5,920 $ 15,828 $ 11,358 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 19,336 $ 7,031 $ 35,422 $ 30,638
Lease Term and Discount Rate	Lease Term and Discount Rate June 30, December 31, 2021 2020 Weighted-average remaining lease term (in years) 8.47 8.36 Weighted-average discount rate 7.17 % 7.60 %
Future Minimum Lease Payments Under Non-cancellable Operating Leases	Future minimum lease payments under non-cancellable operating leases as of June 30, 2021 were as follows (excluding the effect of lease incentives to be received that are recorded in prepaid expenses and other current assets of $7,697 which serve to reduce total lease payments): June 30, 2021 Remainder of 2021 $ 17,310 2022 34,120 2023 33,150 2024 31,899 2025 29,994 Thereafter 127,922 Total lease payments 274,395 Less: interest (71,787) Total lease liabilities $ 202,608

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill balances as of June 30, 2021 and December 31, 2020 were as follows: Goodwill Balance as of December 31, 2020 $ 21,301 Goodwill recorded in connection with acquisitions 5,565 Balance as of June 30, 2021 $ 26,866
Schedule of Intangible Assets and Accumulated Amortization	The following summarizes the Company’s intangible assets and accumulated amortization as of June 30, 2021: June 30, 2021 Original Cost Accumulated Amortization Net Book Value Customer relationships $ 3,700 $ (88) $ 3,612 Total intangible assets $ 3,700 $ (88) $ 3,612
Estimated Future Amortization Expense of Intangible Assets	As of June 30, 2021, estimated future amortization expense related to intangible assets were as follows: June 30, 2021 Remainder of 2021 $ 264 2022 529 2023 529 2024 529 2025 529 Thereafter 1,320 Total $ 3,700

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Net Carrying Amount of Convertible Senior Notes	The net carrying amount of the 2025 Notes was as follows: June 30, 2021 Liabilities: Principal $ 316,250 Unamortized issuance costs (7,343) Net carrying amount $ 308,907
Summary of Interest Expense Recognized Related to Convertible Senior Notes	The following table sets forth the interest expense recognized related to the 2025 Notes: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Contractual interest expense $ 2,372 $ 826 $ 4,744 $ 826 Amortization of debt discount — 1,041 — 1,041 Amortization of issuance costs 468 79 937 79 Total interest expense related to the 2025 Notes $ 2,840 $ 1,946 $ 5,681 $ 1,946

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	The following table summarizes stock option activity under the 2020 Plan: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2020 28,273 $ 18.03 8.20 $ 724,339 Granted 545 42.68 Exercised (2,937) 5.48 Canceled (127) 8.37 Outstanding as of June 30, 2021 25,754 $ 20.03 7.90 $ 429,423 Options exercisable as of June 30, 2021 8,807 $ 5.77 6.48 $ 240,961 Options vested and expected to vest as of June 30, 2021 15,291 $ 20.62 7.89 $ 390,516
Schedule of Additional Information Relating to Tranche	The following table presents additional information relating to each tranche of the Performance Stock Option: Tranche Stock Price Milestone Number of Options Tranche 1 $55 per share 1,330 Tranche 2 $70 per share 1,995 Tranche 3 $90 per share 2,660 Tranche 4 $110 per share 2,660
Summary of RSU Activity	The following table summarizes restricted stock unit activity under the 2020 Plan: Number of Grant Date Unvested and outstanding as of December 31, 2020 1,291 $ 22.14 Granted 1,170 42.00 Vested (258) 22.54 Canceled and forfeited (150) 28.55 Unvested and outstanding as of June 30, 2021 2,053 $ 32.94
Summary of Stock-Based Compensation Expense	Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Sales and marketing $ 964 $ 668 $ 1,987 $ 1,268 General and administrative 25,368 7,695 50,673 17,420 Total $ 26,332 $ 8,363 $ 52,660 $ 18,688

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders were calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Numerator: Net loss $ (41,287) $ (30,301) $ (80,605) $ (64,858) Less: Net loss attributable to noncontrolling interest — — — (704) Net loss attributable to 1Life Healthcare, Inc. stockholders $ (41,287) $ (30,301) $ (80,605) $ (64,154) Denominator: Weighted average common shares outstanding — basic and diluted 136,788 126,150 137,045 105,517 Net loss per share attributable to 1Life Healthcare, Inc. stockholders — basic and diluted $ (0.30) $ (0.24) $ (0.59) $ (0.61)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of June 30, 2021 2020 Options to purchase common stock 25,754 27,636 Unvested restricted stock 2,053 1,320 Warrants to purchase common stock — 162 2025 Notes (1) 7,117 — 34,924 29,118

Nature of the Business and Ba_3

Nature of the Business and Basis of Presentation - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021
Minimum
Restricted Cash and Cash Equivalents Items [Line Items]
Duration of restriction on cash and cash equivalents	1 year
Maximum
Restricted Cash and Cash Equivalents Items [Line Items]
Duration of restriction on cash and cash equivalents	9 years

Nature of the Business and Ba_4

Nature of the Business and Basis of Presentation - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 503,238	$ 112,975	$ 300,675	$ 27,390
Restricted cash, current (included in prepaid expenses and other current assets)	119	119	17	17
Restricted cash, non-current	1,895	1,911	2,014	1,922
Cash, cash equivalents and restricted cash	$ 505,252	$ 115,005	$ 302,706	$ 29,329

Nature of the Business and Ba_5

Nature of the Business and Basis of Presentation - Summary of Customers Representing 10% or More of Accounts Receivables (Details) - Customer Concentration Risk - Accounts Receivable, Net	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Customer A
Product Information [Line Items]
Concentration risk, percentage	13.00%
Customer E
Product Information [Line Items]
Concentration risk, percentage	15.00%	12.00%
Customer F
Product Information [Line Items]
Concentration risk, percentage	16.00%	24.00%
Customer H
Product Information [Line Items]
Concentration risk, percentage	14.00%	16.00%

Nature of the Business and Ba_6

Nature of the Business and Basis of Presentation - Summary of Customers Representing 10% or More of Net Revenue (Details) - Customer Concentration Risk - Net Revenue	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Customer A
Product Information [Line Items]
Concentration risk, percentage	12.00%		12.00%	11.00%
Customer E
Product Information [Line Items]
Concentration risk, percentage		11.00%		11.00%
Customer F
Product Information [Line Items]
Concentration risk, percentage	12.00%	12.00%	12.00%	12.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jan. 01, 2021	Dec. 31, 2020
Liabilities
Convertible senior notes	$ 308,907		$ 308,907			$ 241,233
Stockholders' Equity:
Additional paid-in capital	916,460		916,460			918,118
Accumulated deficit	(444,162)		(444,162)			$ (369,785)
Convertible Senior Notes Due 2025
New Accounting Pronouncement, Early Adoption [Line Items]
Reduction in non-cash interest expense	0	$ (1,041)	0	$ (1,041)
ASU 2020-06 | Convertible Senior Notes Due 2025 | Debt Equity Component
New Accounting Pronouncement, Early Adoption [Line Items]
Reduction in non-cash interest expense	$ 3,239		$ 6,408
ASU 2020-06 | Cumulative Effect Period of Adoption Adjustment
Liabilities
Convertible senior notes					$ 66,737
Stockholders' Equity:
Additional paid-in capital					(73,393)
Accumulated deficit					6,656
ASU 2020-06 | Cumulative Effect, Period of Adoption, Adjusted Balance
Liabilities
Convertible senior notes					307,970
Stockholders' Equity:
Additional paid-in capital					844,725
Accumulated deficit					$ (363,129)

Variable Interest Entities (Det

Variable Interest Entities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Current assets	$ 756,754	$ 774,699
Current liabilities	$ 154,748	117,426
Variable Interest Entity, Primary Beneficiary | PCs
Variable Interest Entity [Line Items]
Term of arrangement, period	10 years
Term of arrangement, renewal period	1 year
Current assets	$ 50,843	48,182
Current liabilities	$ 42,792	$ 31,462

Fair Value Measurements and I_3

Fair Value Measurements and Investments - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Assets:
Short-term investments	$ 150,559	$ 570,023
U.S. Treasury Obligations
Assets:
Short-term investments	60,563	416,158
Foreign Government Bonds
Assets:
Short-term investments	5,055
U.S. Government Agency Securities
Assets:
Short-term investments		20,000
Commercial Paper
Assets:
Short-term investments	84,941	133,865
Money Market Fund
Assets:
Cash equivalents	470,384	50,761
Commercial Paper
Assets:
Cash equivalents		19,999
Recurring
Assets:
Assets	620,943	640,783
Recurring | U.S. Treasury Obligations
Assets:
Short-term investments	60,563	416,158
Recurring | Foreign Government Bonds
Assets:
Short-term investments	5,055
Recurring | U.S. Government Agency Securities
Assets:
Short-term investments		20,000
Recurring | Commercial Paper
Assets:
Short-term investments	84,941	133,865
Recurring | Money Market Fund
Assets:
Cash equivalents	470,384	50,761
Recurring | Commercial Paper
Assets:
Cash equivalents		19,999
Recurring | Level 1
Assets:
Assets	530,947	486,919
Recurring | Level 1 | U.S. Treasury Obligations
Assets:
Short-term investments	60,563	416,158
Recurring | Level 1 | Foreign Government Bonds
Assets:
Short-term investments	0
Recurring | Level 1 | U.S. Government Agency Securities
Assets:
Short-term investments		20,000
Recurring | Level 1 | Commercial Paper
Assets:
Short-term investments	0	0
Recurring | Level 1 | Money Market Fund
Assets:
Cash equivalents	470,384	50,761
Recurring | Level 1 | Commercial Paper
Assets:
Cash equivalents		0
Recurring | Level 2
Assets:
Assets	89,996	153,864
Recurring | Level 2 | U.S. Treasury Obligations
Assets:
Short-term investments	0	0
Recurring | Level 2 | Foreign Government Bonds
Assets:
Short-term investments	5,055
Recurring | Level 2 | U.S. Government Agency Securities
Assets:
Short-term investments		0
Recurring | Level 2 | Commercial Paper
Assets:
Short-term investments	84,941	133,865
Recurring | Level 2 | Money Market Fund
Assets:
Cash equivalents	0	0
Recurring | Level 2 | Commercial Paper
Assets:
Cash equivalents		19,999
Recurring | Level 3
Assets:
Assets	0	0
Recurring | Level 3 | U.S. Treasury Obligations
Assets:
Short-term investments	0	0
Recurring | Level 3 | Foreign Government Bonds
Assets:
Short-term investments	0
Recurring | Level 3 | U.S. Government Agency Securities
Assets:
Short-term investments		0
Recurring | Level 3 | Commercial Paper
Assets:
Short-term investments	0	0
Recurring | Level 3 | Money Market Fund
Assets:
Cash equivalents	$ 0	0
Recurring | Level 3 | Commercial Paper
Assets:
Cash equivalents		$ 0

Fair Value Measurements and I_4

Fair Value Measurements and Investments - Additional Information (Details) - 3.0% Convertible Senior Notes due 2025 - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	May 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate principal amount outstanding	$ 316,250
Interest rate	3.00%		3.00%	3.00%
Convertible notes fair value	$ 351,003	$ 397,472

Fair Value Measurements and I_5

Fair Value Measurements and Investments - Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents, Amortized cost	$ 503,238	$ 112,975	$ 300,675	$ 27,390
Short-term marketable securities, Amortized cost	150,550	570,015
Short-term marketable securities, Gross unrealized gains (losses)	9	8
Short-term marketable securities, Fair value	150,559	570,023
Total cash equivalents and short-term marketable securities, Amortized cost	620,934	640,775
Total cash equivalents and short-term marketable securities, Fair value	620,943	640,783
U.S. Treasury Obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term marketable securities, Amortized cost	60,553	416,150
Short-term marketable securities, Gross unrealized gains (losses)	10	8
Short-term marketable securities, Fair value	60,563	416,158
Foreign Government Bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term marketable securities, Amortized cost	5,056
Short-term marketable securities, Gross unrealized gains (losses)	(1)
Short-term marketable securities, Fair value	5,055
U.S. Government Agency Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term marketable securities, Amortized cost		20,000
Short-term marketable securities, Gross unrealized gains (losses)		0
Short-term marketable securities, Fair value		20,000
Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term marketable securities, Amortized cost	84,941	133,865
Short-term marketable securities, Gross unrealized gains (losses)	0	0
Short-term marketable securities, Fair value	84,941	133,865
Cash Equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents, Amortized cost		70,760
Cash equivalents, Fair value		70,760
Money Market Fund
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents, Amortized cost	470,384	50,761
Cash equivalents, Fair value	$ 470,384	50,761
Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents, Amortized cost		19,999
Cash equivalents, Fair value		$ 19,999

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Net revenue	$ 120,416	$ 78,000	$ 241,768	$ 156,756
Net Patient Service Revenue
Disaggregation of Revenue [Line Items]
Net revenue	43,416	23,927	87,878	58,013
Partnership Revenue
Disaggregation of Revenue [Line Items]
Net revenue	56,126	33,993	111,057	63,448
Net Patient Service and Partnership Revenue
Disaggregation of Revenue [Line Items]
Net revenue	99,542	57,920	198,935	121,461
Membership Revenue
Disaggregation of Revenue [Line Items]
Net revenue	20,874	17,680	41,070	32,895
Grant Income
Disaggregation of Revenue [Line Items]
Net revenue	$ 0	$ 2,400	$ 1,763	$ 2,400

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Net Patient Service Revenue by Source (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Net revenue	$ 120,416	$ 78,000	$ 241,768	$ 156,756
Net Patient Service Revenue
Disaggregation of Revenue [Line Items]
Net revenue	43,416	23,927	87,878	58,013
Commercial and Government Third-Party Payers | Health Care, Other
Disaggregation of Revenue [Line Items]
Net revenue	39,608	20,985	81,843	50,876
Patients, Including Self-Pay, Insurance Co-Pays and Deductibles | Health Care, Patient Service
Disaggregation of Revenue [Line Items]
Net revenue	$ 3,808	$ 2,942	$ 6,035	$ 7,137

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Net revenue	$ 120,416,000	$ 78,000,000	$ 241,768,000	$ 156,756,000
Contract with customer, liability, revenue recognized	20,041,000	15,995,000	26,187,000	17,458,000
Deferred revenue recognized related to variable consideration	6,356,000		6,356,000
Contract with customer liability related to variable consideration non-current	5,351,000		5,351,000
Grant Income
Disaggregation of Revenue [Line Items]
Net revenue	0	$ 2,400,000	1,763,000	$ 2,400,000
CARES Act | COVID-19 | Grant Income
Disaggregation of Revenue [Line Items]
Net revenue	$ 0		$ 1,763,000

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Contract Assets and Deferred Revenue (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Balances from contracts with customers:
Accounts receivable	$ 55,982	$ 67,895
Contract asset (included in prepaid expenses and other current assets)	788	513
Deferred revenue	$ 50,355	$ 43,590

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Remaining Performance Obligation (Details) $ in Thousands	Jun. 30, 2021USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 13,862
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 4,676
Revenue remaining performance obligation, expected timing of satisfaction, period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 9,186
Revenue remaining performance obligation, expected timing of satisfaction, period

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Lessee, Lease, Description [Line Items]
Operating leases, options to terminate	Certain lease agreements contain options to terminate the lease before maturity.
Prepaid Expenses and Other Current Assets
Lessee, Lease, Description [Line Items]
Lease incentives to be received	$ 7,697
Minimum
Lessee, Lease, Description [Line Items]
Operating leases, options to extend leases term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Operating leases, options to extend leases term	7 years

Leases - Components of Operatin

Leases - Components of Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Operating lease costs	$ 7,856	$ 6,355	$ 15,189	$ 12,315
Variable lease costs	1,222	1,013	2,533	2,029
Total lease costs	$ 9,078	$ 7,368	$ 17,722	$ 14,344

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 7,973	$ 5,920	$ 15,828	$ 11,358
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$ 19,336	$ 7,031	$ 35,422	$ 30,638

Leases - Lease Term and Discoun

Leases - Lease Term and Discount Rate (Details)	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term (in years)	8 years 5 months 19 days	8 years 4 months 9 days
Weighted-average discount rate	7.17%	7.60%

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments Under Non-cancellable Operating Leases (Details) $ in Thousands	Jun. 30, 2021USD ($)
Leases [Abstract]
Remainder of 2021	$ 17,310
2022	34,120
2023	33,150
2024	31,899
2025	29,994
Thereafter	127,922
Total lease payments	274,395
Less: interest	(71,787)
Total lease liabilities	$ 202,608

Business Combinations (Details)

Business Combinations (Details) $ in Thousands	Jun. 06, 2021USD ($)shares	Jun. 30, 2021USD ($)business_acquired	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jul. 13, 2021	Dec. 31, 2020USD ($)
Business Acquisition [Line Items]
Cash consideration			$ 9,695	$ 0
Goodwill		$ 26,866	26,866			$ 21,301
Acquisition related expenses			11,148
Iora
Business Acquisition [Line Items]
Receipt (payment) of termination fee	$ 50,000
Subsequent Event | Current 1Life Stockholders
Business Acquisition [Line Items]
Percentage of ownership after acquisition					78.00%
Subsequent Event | Former Iora Stockholders
Business Acquisition [Line Items]
Percentage of ownership after acquisition					22.00%
Customer relationships
Business Acquisition [Line Items]
Intangibles, useful lives		7 years
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Number of acquisitions | business_acquired		2
Cash consideration		$ 9,350
Goodwill		5,565	5,565
Series of Individually Immaterial Business Acquisitions | Customer relationships
Business Acquisition [Line Items]
Acquired intangibles		$ 3,700	$ 3,700
Iora
Business Acquisition [Line Items]
Number of shares to be converted per each acquiree share | shares	0.689
Number of shares to be issued or reserved for issuance | shares	56,100,000
Receipt (payment) of termination fee	$ (50,000)
Iora | Maximum
Business Acquisition [Line Items]
Transaction costs	$ 10,000

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairments	$ 0	$ 0
Goodwill [Roll Forward]
Balance as of December 31, 2020		21,301,000
Goodwill recorded in connection with acquisitions	5,565,000	5,565,000
Balance as of June 30, 2021	$ 26,866,000	$ 26,866,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets and Accumulated Amortization (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)
Finite-Lived Intangible Assets [Line Items]
Acquired intangibles	$ 3,700	$ 3,700
Original Cost	3,700	3,700
Accumulated Amortization	(88)	(88)
Net Book Value	3,612	3,612
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Original Cost	3,700	3,700
Accumulated Amortization	(88)	(88)
Net Book Value	$ 3,612	$ 3,612

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Estimated Future Amortization (Details) $ in Thousands	Jun. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2021	$ 264
2022	529
2023	529
2024	529
2025	529
Thereafter	1,320
Total	$ 3,700

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	May 31, 2020USD ($)Tradingday$ / sharesshares	Jun. 30, 2021USD ($)shares	Jun. 30, 2020USD ($)shares
3.0% Convertible Senior Notes due 2025
Debt Instrument [Line Items]
Debt instrument face amount	$ 275,000		$ 41,250
Interest rate	3.00%	3.00%	3.00%
Proceeds from debt offering	$ 306,868
Debt instrument convertible conversion amount	$ 1
Debt converted to common stock (in shares) | shares	22.5052
Debt instrument conversion price (in usd per share) | $ / shares	$ 44.43
Debt instrument, redemption threshold trading days | Tradingday	20
Debt instrument, redemption consecutive trading days | Tradingday	30
Debt instrument, repurchase price percentage	100.00%
Debt instrument, redemption conversion percentage	130.00%
Convertible Senior Notes Due 2025
Debt Instrument [Line Items]
Debt converted to common stock (in shares) | shares		7,117,000	0
Debt issuance costs		$ 9,374
Debt instrument effective interest rate		0.65%
Conversion Scenario One | 3.0% Convertible Senior Notes due 2025
Debt Instrument [Line Items]
Debt instrument conversion percentage	130.00%
Debt instrument consecutive trading days | Tradingday	30
Debt instrument, threshold trading days | Tradingday	20
Conversion Scenario Two | 3.0% Convertible Senior Notes due 2025
Debt Instrument [Line Items]
Debt instrument convertible conversion amount	$ 1
Percentage applied to product of common stock price and conversion rate	98.00%

Convertible Senior Notes - Summ

Convertible Senior Notes - Summary of Net Carrying Amount of Liability Component of Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 $ in Thousands	Jun. 30, 2021USD ($)
Debt Instrument [Line Items]
Principal	$ 316,250
Unamortized issuance costs	(7,343)
Net carrying amount	$ 308,907

Convertible Senior Notes - Su_2

Convertible Senior Notes - Summary of Interest Expense Recognized Related to Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Debt Instrument [Line Items]
Contractual interest expense	$ 2,372	$ 826	$ 4,744	$ 826
Reduction in non-cash interest expense	0	1,041	0	1,041
Amortization of issuance costs	468	79	937	79
Total interest expense related to the 2025 Notes	$ 2,840	$ 1,946	$ 5,681	$ 1,946

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2020shares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)trancheshares	Jun. 30, 2020USD ($)	Jan. 01, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense		$ 26,332	$ 8,363	$ 52,660	$ 18,688
Unrecognized compensation expense related to service-based options		14,805	32,690	$ 14,805	$ 32,690
Weighted-average period over which unrecognized compensation cost is expected to be recognized				1 year 9 months 18 days	2 years
Fair value of options granted		50	3,180	$ 12,218	$ 4,429
Tax benefits related to stock based awards		2,248	92	$ 32,642	372
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				7 years
Stock based compensation expense		14,924		$ 29,850
Number of options granted (in shares) | shares				8,645,000
Number of tranches | tranche				4
Achievement of pre-determined increases, period				90 days
Aggregate stock-based compensation expense if service-based vesting conditions are met				$ 197,469
Unamortized stock-based compensation expense		$ 167,128		$ 167,128
2007 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional stock awards granted (in shares) | shares	0
2017 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional stock awards granted (in shares) | shares	0
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of number of shares of common stock outstanding	4.00%
Number of shares available for future grants | shares		11,346,000		11,346,000
2020 Equity Incentive Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Term of options granted	10 years
2020 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future grants | shares		4,361,000		4,361,000
Common stock reserved for future issuance (in shares) | shares	2,800,000					2,017,000
ESPP, offering period				6 months
Issuance of common stock under the employee stock purchase plan (in shares) | shares		107,000
Weighted-average price of shares purchased (in usd per share) | $ / shares		$ 27.85
Stock based compensation expense		$ 591	$ 597	$ 1,212	$ 1,006

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - 2020 Plan $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Number of Options
Outstanding as of beginning of period (in shares) | shares	28,273
Granted (in shares) | shares	545
Exercised (in shares) | shares	(2,937)
Canceled (in shares) | shares	(127)
Outstanding as of end of period (in shares) | shares	25,754	28,273
Number of Options, Options exercisable as of end of period (in shares) | shares	8,807
Number of Options, Option vested and expected to vest as of end of period (in shares) | shares	15,291
Weighted- Average Exercise Price
Outstanding as of beginning of period (in usd per share) | $ / shares	$ 18.03
Granted (in usd per share) | $ / shares	42.68
Exercised (in usd per share) | $ / shares	5.48
Canceled (in usd per share) | $ / shares	8.37
Outstanding as of end of period (in usd per share) | $ / shares	20.03	$ 18.03
Weighted-Average Exercise Price, Options exercisable (in usd per share) | $ / shares	5.77
Weighted-Average Exercise Price, Options vested and expected to vest (in usd per share) | $ / shares	$ 20.62
Weighted-Average Remaining Contractual Term (Years), Outstanding	7 years 10 months 24 days	8 years 2 months 12 days
Weighted-Average Remaining Contractual Term (Years), Options exercisable	6 years 5 months 23 days
Weighted-Average Remaining Contractual Term (Years), Options vested and expected to vest	7 years 10 months 20 days
Aggregate Intrinsic Value, Outstanding | $	$ 429,423	$ 724,339
Aggregate Intrinsic Value, Options exercisable | $	240,961
Aggregate Intrinsic Value, Options vested and expected to vest | $	$ 390,516

Stock-Based Compensation - Tran

Stock-Based Compensation - Tranches of Performance Stock Option (Details) - Performance Shares shares in Thousands	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Tranche 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) | $ / shares	$ 55
Number of Options (in shares) | shares	1,330
Tranche 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) | $ / shares	$ 70
Number of Options (in shares) | shares	1,995
Tranche 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) | $ / shares	$ 90
Number of Options (in shares) | shares	2,660
Tranche 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) | $ / shares	$ 110
Number of Options (in shares) | shares	2,660

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity (Details) - 2020 Plan - Restricted Stock Unit shares in Thousands	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Number of Shares
Unvested and outstanding as of beginning of period (in shares) | shares	1,291
Granted (in shares) | shares	1,170
Vested (in shares) | shares	(258)
Canceled and forfeited (in shares) | shares	(150)
Unvested and outstanding as of end of period (in shares) | shares	2,053
Grant Date Fair Value
Unvested and outstanding as of beginning of period (in usd per share) | $ / shares	$ 22.14
Granted (in usd per share) | $ / shares	42
Vested (in usd per share) | $ / shares	22.54
Canceled and forfeited (in usd per share) | $ / shares	28.55
Unvested and outstanding as of end of period (in usd per share) | $ / shares	$ 32.94

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 26,332	$ 8,363	$ 52,660	$ 18,688
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	964	668	1,987	1,268
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 25,368	$ 7,695	$ 50,673	$ 17,420

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes	$ (4,040)	$ (22)	$ 159	$ (72)
Effective income tax rate	8.913%	0.075%	(0.198%)	0.124%

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net loss	$ (41,287)	$ (39,318)	$ (30,301)	$ (34,557)	$ (80,605)	$ (64,858)
Less: Net loss attributable to noncontrolling interest	0		0		0	(704)
Net loss attributable to 1Life Healthcare, Inc. stockholders	$ (41,287)		$ (30,301)		$ (80,605)	$ (64,154)
Denominator:
Weighted average common shares outstanding — basic (in shares)	136,788		126,150		137,045	105,517
Net loss per share attributable to 1Life Healthcare, Inc. stockholders — diluted (in usd per share)	$ (0.30)		$ (0.24)		$ (0.59)	$ (0.61)
Weighted average common shares outstanding — diluted (in shares)	136,788		126,150		137,045	105,517
Net loss per share attributable to 1Life Healthcare, Inc. stockholders — basic (in usd per share)	$ (0.30)		$ (0.24)		$ (0.59)	$ (0.61)

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	34,924	29,118
Convertible Senior Notes Due 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Debt converted to common stock (in shares)	7,117	0
Options to Purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	25,754	27,636
Unvested Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	2,053	1,320
Warrants to Purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	0	162

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Litigation liabiity	$ 11,500
Insurers committed amount	5,950
Litigation settlement amount	$ 5,550

Note Receivable (Details)

Note Receivable (Details) - USD ($) $ in Thousands	Aug. 02, 2021	Jun. 21, 2021	Jun. 30, 2021	Jun. 30, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Advances made			$ 20,000	$ 0
Iora
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable outstanding			$ 20,000
Effective period of loan agreement		30 days
Interest rate on notes receivable		10.00%
Iora | Subsequent Event
Accounts, Notes, Loans and Financing Receivable [Line Items]
Advances made	$ 10,000
Iora | Six-month anniversary of termination date
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate on notes receivable		5.00%
Iora | 12-month anniversary of termination date
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate on notes receivable		5.00%
Iora | Following the merger termination
Accounts, Notes, Loans and Financing Receivable [Line Items]
Maturity period of loan agreement		18 months
Iora | Following the earliest of certain maturity dates set forth in the SVB Facility
Accounts, Notes, Loans and Financing Receivable [Line Items]
Maturity period of loan agreement		90 days
Iora | Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable outstanding		$ 75,000
Interest rate on notes receivable		20.00%